ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features

blonca9
Jun 27
1 min read

He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same place. Plus, writing in logic gating, harnessing shRNA, and more. The company recently raised a $325M series C.

Recent Posts

See All

Jefferies London: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset

Jefferies London: Zealand Pharma CEO Adam Steensberg believes that amylins will overtake GLPs as the backbones of obesity treatments in the future

Jefferies London: Nanobiotix has a new platform that is meant to help RNA/DNA-based therapies, gene therapies, oncolytic viruses and other liver-delivered medicines have better efficacy

ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight